Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

ClinicalTrials.gov ID: NCT01527006

Public ClinicalTrials.gov record NCT01527006. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate the pharmacokinetics, efficacy, and safety of perampanel oral suspension on seizure frequency in pediatric participants maintained on one to three stable antiepileptic drugs

Study identification

NCT ID: NCT01527006
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eisai Inc.; Industry
Enrollment: 63 participants

Conditions and interventions

Conditions

Central Nervous System

Interventions

perampanel Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 11 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2012 (Type not available)
Primary completion: May 2014 (Actual)
Completion: Apr 2015 (Actual)
Last update posted: Jul 12, 2016

2012 – 2015

United States locations

U.S. sites: 23
U.S. states: 16
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Aurora	Colorado	—	—
Not listed	Washington D.C.	District of Columbia	—	—
Not listed	Gulf Breeze	Florida	—	—
Not listed	Jacksonville	Florida	—	—
Not listed	Miami	Florida	—	—
Not listed	Orlando	Florida	—	—
Not listed	Tampa	Florida	—	—
Not listed	Augusta	Georgia	—	—
Not listed	Indianapolis	Indiana	—	—
Not listed	Lexington	Kentucky	—	—
Not listed	Shreveport	Louisiana	—	—
Not listed	Chesterfield	Missouri	—	—
Not listed	Columbia	Missouri	—	—
Not listed	Gibbsboro	New Jersey	—	—
Not listed	Buffalo	New York	—	—
Not listed	Akron	Ohio	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Pittsburgh	Pennsylvania	—	—
Not listed	Memphis	Tennessee	—	—
Not listed	San Antonio	Texas	—	—
Not listed	Salt Lake City	Utah	—	—
Not listed	Richmond	Virginia	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01527006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 12, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01527006 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →